密骨胶囊对血清抗酒石酸酸性磷酸酶和Ⅰ型胶原C末端肽的影响

摘要

目的 观察密骨胶囊对骨吸收参数指标血清抗酒石酸酸性磷酸酶、血清Ⅰ型胶原C末端肽的影响.方法 临床选择136例原发性骨质疏松症患者随机分为两组,其中对照组66例给予口服钙尔奇D片,治疗组70例在对照组基础上给予密骨胶囊口服治疗,各组均经6个月治疗.分别于患者服药前和服药后1、3、6个月抽血,用ELISA法测其血清中1型胶原C末端肽、血清抗酒石酸酸性磷酸酶含量.结果 用药1个月后,两组血清骨吸收参数值较治疗前明显下降(P＜0.05)；用药3个月后,治疗组骨代谢指标下降非常明显(P＜0.01),基本达到正常值；患者服药6个月后,治疗组血清抗酒石酸酸性磷酸酶与对照组比较有统计学意义(P＜0.05).结论 密骨胶囊能够明显降低血清中的Ⅰ型胶原C末端肽和血清抗酒石酸酸性磷酸酶的水平,阻止骨量丢失,抑制过高的骨转换,使骨的代谢达到新的平衡,提高骨质量,具有明显的抑制骨吸收的作用.%Objective To observe the clinical effects of Migu capsule on the targets of bone absorption parameters,such as TRACP5b and CTX. Methods 136 patients with primary osteoporosis were divided into two groups randomly. There are 70 cases in treatment group and 66 cases in the control group. Control group were treated with Cal-trate D. Treatment group were treated with Migu capsule and Caltrate D. The patients were all treated for 6 months. TRACP5b and CTX of them were mersured by euzymelinked immunosorbem assay. TRACP5b and CTX were detected by euzymelinked immunosorbent assay before and after being treated. Results 1 month after being treated, TRACP5b and CTX in both groups decreased significantly (P<0.05).3 month later,the TRACP5b and CTX in treatment groups decreased significantly (P<0.01),it could achieve the normal value. 6 month after being treated, compared with Control group,TRACP5b and CTX in Treatment group decrease significantly (P<0. 01). Conclusion Migu capsule can obviously degrade the values of TRACP5b and CTX in serum,prevent the loss of bone mass,restrain exorbitant bone commutation to make bone metabolism in balance and elevate bone quality. It had conspicuous function of restrainning bone sorption.